The DSP Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, featuring targeted disruption of the DSP gene encoding desmoplakin. This product provides a heterogeneous pool of gene-edited cells, enabling robust loss-of-function studies without clonal selection. The knockout model serves as a valuable tool for investigating desmosome biology, cell adhesion, and desmoplakin-dependent signaling pathways in an epithelial cancer context.
HeLa cells are an immortalized human cervical adenocarcinoma line, originally isolated from a patient with cervical cancer and known to be positive for human papillomavirus type 18 (HPV18). As a widely used model in cancer biology, HeLa cells offer rapid proliferation, reliable culture, and well-characterized signaling networks. Their epithelial derivation makes them particularly suitable for examining cell-cell adhesion, migration, and cytoskeletal organization, all of which are directly impacted by desmosomal protein function.
Desmoplakin, encoded by DSP, is a critical desmosomal plaque protein that physically links intermediate filaments to desmosomal cadherin complexes. Through its C-terminal domain, desmoplakin binds keratin intermediate filaments (primarily KRT5 and KRT14) and anchors them to the desmosomal core via interactions with plakoglobin (JUP) and plakophilin-2 (PKP2). This linkage connects to the transmembrane cadherins DSG1 and DSC3, forming the adhesive intercellular junction. Transcriptional activation of DSP is mediated by TP63 and the canonical Wnt pathway effector Wnt3a, while downstream, DSP loss can alter expression of KRT5, KRT14, DSG1, DSG3, and JUP. CRISPR/Cas9-mediated disruption of DSP thus uncouples intermediate filaments from desmosomes, compromising desmosome assembly, keratinocyte differentiation, and actin cytoskeleton regulation.
In the HeLa cervical adenocarcinoma background, loss of desmoplakin is anticipated to impair intercellular adhesion, potentially enhancing migratory and invasive behavior. This model is therefore highly relevant for dissecting the role of desmosomal integrity in cancer progression. Additionally, it provides a platform to study inherited disorders linked to desmoplakin dysfunction, including arrhythmogenic right ventricular cardiomyopathy, palmoplantar keratoderma, and skin fragility syndromes. The polyclonal composition of the knockout product ensures broad representation of editing outcomes, minimizing clonal artifacts and strengthening functional conclusions.
Typical applications include Western blotting and immunofluorescence to verify desmoplakin ablation and assess desmosome protein expression, co-immunoprecipitation to probe protein-protein interactions, and cell adhesion and migration assays to measure functional consequences. The cells are also suited for transcriptomic analyses by RNA-seq or qRT-PCR to evaluate downstream gene expression changes, and for high-throughput drug sensitivity screens targeting desmosome-related pathways. For detailed product validation and customized application support, please contact Ascent Research.
